RecruitingPhase 3NCT07236814

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting


Sponsor

Capital Medical University

Enrollment

384 participants

Start Date

Nov 28, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.


Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Oseltamivir, a drug called Oseltamivir Placebo, and others for people with influenza. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSuraxavir marboxil

Suraxavir marboxil (40mg on the first day)

DRUGOseltamivir Placebo

Oseltamivir placebo(75mg each day during the first five days)

DRUGOseltamivir

Oseltamivir (75mg each day during the first five days)

DRUGSuraxavir marboxil placebo

Suraxavir marboxil placebo (40mg on the first day).


Locations(2)

China-Japan Friendship hospital, Beijing, Beijing

Beijing, Beijing Municipality, China

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07236814


Related Trials